CL2018002692A1 - Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) - Google Patents
Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)Info
- Publication number
- CL2018002692A1 CL2018002692A1 CL2018002692A CL2018002692A CL2018002692A1 CL 2018002692 A1 CL2018002692 A1 CL 2018002692A1 CL 2018002692 A CL2018002692 A CL 2018002692A CL 2018002692 A CL2018002692 A CL 2018002692A CL 2018002692 A1 CL2018002692 A1 CL 2018002692A1
- Authority
- CL
- Chile
- Prior art keywords
- virus
- divisional application
- vaccine against
- flu virus
- swine flu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
LA PRESENTE INVENCIÓN DESCRIBE A UNA COMPOSICIÓN INMUNOGÉNICA QUE COMPRENDE: A) UN VIRUS H3 VIVO MODIFICADO DE GRIPE PORCINA Y B) UN VIRUS H1 VIVO MODIFICADO DE GRIPE PORCINA. TAMBIÉN DESCRIBE MÉTODOS PARA INMUNIZAR UN SUJETO QUE COMPRENDE LA ADMINISTRACIÓN DE DICHA COMPOSICIÓN INMUNOGÉNICA. ADEMÁS DESCRIBE MÉTODOS DE TRATAMIENTO O PREVENCIÓN DE LOS SIGNOS CLÍNICOS CAUSADOS POR VIRUS DE LA GRIPE PORCINA, QUE COMPRENDE LA ADMINISTRACIÓN DE DICHA COMPOSICIÓN INMUNOGÉNICA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562121181P | 2015-02-26 | 2015-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018002692A1 true CL2018002692A1 (es) | 2019-01-18 |
Family
ID=55487152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017001961A CL2017001961A1 (es) | 2015-02-26 | 2017-08-01 | Vacuna bivalente contra el virus de gripe porcina |
CL2018002692A CL2018002692A1 (es) | 2015-02-26 | 2018-09-24 | Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017001961A CL2017001961A1 (es) | 2015-02-26 | 2017-08-01 | Vacuna bivalente contra el virus de gripe porcina |
Country Status (13)
Country | Link |
---|---|
US (2) | US10029005B2 (es) |
EP (1) | EP3261664A1 (es) |
JP (1) | JP6722686B2 (es) |
KR (1) | KR20170122786A (es) |
CN (1) | CN107250353B (es) |
AU (1) | AU2016222962B2 (es) |
BR (1) | BR112017015789A2 (es) |
CL (2) | CL2017001961A1 (es) |
EA (1) | EA201791907A1 (es) |
MX (1) | MX2017010908A (es) |
PH (1) | PH12017501370A1 (es) |
TW (1) | TWI711462B (es) |
WO (1) | WO2016137929A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727880A (zh) | 2004-06-01 | 2012-10-17 | 西奈山医学院 | 遗传工程猪流感病毒及其应用 |
KR20170122786A (ko) | 2015-02-26 | 2017-11-06 | 베링거잉겔하임베트메디카게엠베하 | 2가 돼지 인플루엔자 바이러스 백신 |
BR112020012049A2 (pt) * | 2017-12-18 | 2020-11-24 | Intervet International B.V. | vacina contra vírus da influenza a suína |
WO2019121414A1 (en) | 2017-12-20 | 2019-06-27 | Boehringer Ingelheim Vetmedica Gmbh | Detection of modified live swine influenza virus vaccines |
US20210353738A1 (en) * | 2018-09-21 | 2021-11-18 | Nutech Ventures | Methods of making and using universal centralized influenza vaccine genes |
KR20210084596A (ko) * | 2018-10-31 | 2021-07-07 | 베링거잉겔하임베트메디카게엠베하 | 이종 스파이크 단백질을 갖는 h52 ibv 백신 |
EP3873516A1 (en) * | 2018-10-31 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | 4/91 ibv vaccine with heterologous spike protein |
MX2019014943A (es) | 2018-12-12 | 2020-08-06 | Cambridge Tech Llc | Vacuna universal contra la gripe. |
WO2021173965A1 (en) * | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
CN113186173B (zh) * | 2021-04-15 | 2023-03-31 | 上海生物制品研究所有限责任公司 | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4071618A (en) | 1974-09-03 | 1978-01-31 | Research Foundation For Microbial Diseases Of Osaka University | Process for preparing virus disease live vaccines |
JPS57136528A (en) | 1981-02-09 | 1982-08-23 | Hayashibara Biochem Lab Inc | Preparation of viral vaccine |
JPS5939831A (ja) | 1982-08-27 | 1984-03-05 | Biseibutsu Kagaku Kenkyusho:Kk | 豚用インフルエンザウイルス不活化ワクチン |
US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
JPS60202827A (ja) | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
US5786199A (en) | 1989-08-28 | 1998-07-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
US5840520A (en) | 1989-08-28 | 1998-11-24 | Aviron | Recombinant negative strand RNA virus expression systems |
US5766601A (en) | 1990-08-08 | 1998-06-16 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
JPH07502496A (ja) | 1991-10-07 | 1995-03-16 | バイオゲン インコーポレイテッド | Cd2/lfa−3相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法 |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
DE69311764T2 (de) | 1992-05-14 | 1998-02-05 | Polymun Scient Immunbio Forsch | Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren |
US7344722B1 (en) | 1993-06-29 | 2008-03-18 | The Regents Of The University Of Michigan | Cold-adapted influenza virus |
EP1394259A3 (en) | 1994-07-18 | 2004-04-14 | Karl-Klaus Prof. Dr. Conzelmann | Recombinant infectious non-segmented negative strand RNA virus |
US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
US6146873A (en) | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
EP0780475B2 (en) | 1995-08-09 | 2006-07-19 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Process for the production of infectious negative-strand RNA viruses |
US5840565A (en) | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
WO1997012032A1 (en) | 1995-09-27 | 1997-04-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
AU3799797A (en) | 1996-07-15 | 1998-02-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
WO1998013501A2 (en) | 1996-09-27 | 1998-04-02 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales |
TR199902561T2 (xx) | 1997-03-05 | 2000-02-21 | Ribogene, Inc. | Hepatit C vir�s replikasyonunun se�ici bi�imde engelleyen maddelerin belirlenmesi i�in yeni tarama y�ntemleri |
US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
US6884414B1 (en) | 1997-04-30 | 2005-04-26 | Mount Sinai School Of Medicine Of New York University | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents |
ATE501259T1 (de) | 1997-05-23 | 2011-03-15 | Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services | Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen |
CA2295858C (en) | 1997-07-11 | 2011-05-10 | Yale University | Rhabdoviruses with reengineered coats |
CN1273603A (zh) | 1997-09-19 | 2000-11-15 | 美国氰胺公司 | 减毒的呼吸道合胞病毒 |
WO1999064571A1 (en) | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
PL200977B1 (pl) | 1998-06-12 | 2009-02-27 | Sinai School Medicine | Atenuowany wirus grypy, genetycznie zmodyfikowany atenuowany wirus grypy, kompozycje szczepionek i kompozycje farmaceutyczne |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
DE60033284T3 (de) | 1999-07-14 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | In vitro-rekonstitution von segmentierten, negativstrang-rna-viren |
AU2001250352B2 (en) | 2000-03-02 | 2006-01-12 | Polymun Scientific Immunbiologische Forschung Gmbh | Recombinant influenza a viruses |
US6635416B2 (en) | 2000-04-10 | 2003-10-21 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
DE10020505A1 (de) | 2000-04-26 | 2001-10-31 | Conzelmann Karl Klaus | RSV NS Proteine antagonisieren die Interferon (IFN) Antwort |
AU2356002A (en) | 2000-09-25 | 2002-04-02 | Polymun Scient Immunbio Forsch | Live vaccine and method of manufacture |
JP2006506101A (ja) | 2002-11-13 | 2006-02-23 | ルトガーズ、ザ ステイト ユニバーシティ | インフルエンザウイルス非構造タンパク質1の阻害剤を設計する方法 |
CN102727880A (zh) * | 2004-06-01 | 2012-10-17 | 西奈山医学院 | 遗传工程猪流感病毒及其应用 |
EP1855713B1 (en) | 2005-02-15 | 2016-04-27 | Mount Sinai School of Medicine | Genetically engineered equine influenza virus and uses thereof |
US20070116717A1 (en) | 2005-08-01 | 2007-05-24 | Shneider Alexander M | Influenza vaccine compositions and methods |
AT502275B8 (de) | 2005-08-08 | 2007-08-15 | Greenhills Biotechnology Res D | Immunantwort-induzierende zusammensetzungen |
PL2529747T3 (pl) | 2005-12-02 | 2018-08-31 | Icahn School Of Medicine At Mount Sinai | Chimeryczne wirusy prezentuące nienatywne białka powierzchniowe i zastosowania tych wirusów |
US7507411B2 (en) | 2006-06-23 | 2009-03-24 | University Of Saskatchewan | Attenuated influenza NS1 variants |
WO2011014504A1 (en) | 2009-07-27 | 2011-02-03 | Mount Sinai School Of Medicine Of New York University | Recombinant influenza virus vectors and uses thereof |
CN102166352B (zh) * | 2011-04-13 | 2013-01-23 | 华威特(北京)生物科技有限公司 | 猪流感二价灭活疫苗的制备方法及其产品 |
US20130189303A1 (en) * | 2011-08-02 | 2013-07-25 | Yan Zhou | Recombinant swine influenza virus and uses thereof |
EP2764015A1 (en) * | 2011-10-07 | 2014-08-13 | Medlmmune, LLC | Influenza hemagglutinin variants |
CN103468647B (zh) * | 2013-09-03 | 2015-04-22 | 华中农业大学 | 猪流感h1n1和h3n2亚型的二价灭活疫苗 |
KR20170122786A (ko) | 2015-02-26 | 2017-11-06 | 베링거잉겔하임베트메디카게엠베하 | 2가 돼지 인플루엔자 바이러스 백신 |
-
2016
- 2016-02-23 KR KR1020177027129A patent/KR20170122786A/ko unknown
- 2016-02-23 CN CN201680010359.4A patent/CN107250353B/zh active Active
- 2016-02-23 MX MX2017010908A patent/MX2017010908A/es unknown
- 2016-02-23 EA EA201791907A patent/EA201791907A1/ru unknown
- 2016-02-23 EP EP16708874.9A patent/EP3261664A1/en active Pending
- 2016-02-23 JP JP2017545386A patent/JP6722686B2/ja not_active Expired - Fee Related
- 2016-02-23 US US15/050,640 patent/US10029005B2/en active Active
- 2016-02-23 AU AU2016222962A patent/AU2016222962B2/en not_active Ceased
- 2016-02-23 BR BR112017015789A patent/BR112017015789A2/pt not_active IP Right Cessation
- 2016-02-23 WO PCT/US2016/019037 patent/WO2016137929A1/en active Application Filing
- 2016-02-25 TW TW105105727A patent/TWI711462B/zh not_active IP Right Cessation
-
2017
- 2017-07-31 PH PH12017501370A patent/PH12017501370A1/en unknown
- 2017-08-01 CL CL2017001961A patent/CL2017001961A1/es unknown
-
2018
- 2018-06-22 US US16/015,512 patent/US10905756B2/en active Active
- 2018-09-24 CL CL2018002692A patent/CL2018002692A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20160250318A1 (en) | 2016-09-01 |
AU2016222962A1 (en) | 2017-07-13 |
TWI711462B (zh) | 2020-12-01 |
US20180289795A1 (en) | 2018-10-11 |
EA201791907A1 (ru) | 2018-02-28 |
BR112017015789A2 (pt) | 2018-03-27 |
CN107250353B (zh) | 2021-07-23 |
EP3261664A1 (en) | 2018-01-03 |
CL2017001961A1 (es) | 2018-04-20 |
US10029005B2 (en) | 2018-07-24 |
WO2016137929A1 (en) | 2016-09-01 |
KR20170122786A (ko) | 2017-11-06 |
US10905756B2 (en) | 2021-02-02 |
JP6722686B2 (ja) | 2020-07-15 |
TW201701900A (zh) | 2017-01-16 |
CN107250353A (zh) | 2017-10-13 |
MX2017010908A (es) | 2017-12-07 |
AU2016222962B2 (en) | 2020-05-21 |
JP2018512388A (ja) | 2018-05-17 |
PH12017501370A1 (en) | 2017-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002692A1 (es) | Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) | |
CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
CL2018002874A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). | |
BR112016025819A2 (pt) | vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico | |
BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
BR112013020743A2 (pt) | composições e métodos para a terapia e diagnóstico de influenza | |
GT201700179A (es) | Formulaciones en polvo nasal para el tratamiento de hipoglicemia | |
BR112018003967A2 (pt) | tratamento de hipersensibilidade à picada de inseto | |
BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
CO2021006308A2 (es) | Proteínas f de prefusión del vrs estabilizadas | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
CL2019000722A1 (es) | Nueva vacuna contra la gripe porcina. | |
AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
BR112017005231A2 (pt) | formulações eutéticas de cloridrato de ciclobenzaprina | |
CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
CL2019001200A1 (es) | Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta. | |
BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
NI201800105A (es) | Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos. |